Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy

Description

The overall purpose of this study is to evaluate cardiopulmonary toxicity in patients with lung cancer (NSCLC or SCLC) undergoing combined thoracic radiotherapy ± chemotherapy and immunotherapy through timed monitoring and blood sample collection and to identify correlative biomarkers for predicting cardiopulmonary adverse events.

Conditions

Lung Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

The overall purpose of this study is to evaluate cardiopulmonary toxicity in patients with lung cancer (NSCLC or SCLC) undergoing combined thoracic radiotherapy ± chemotherapy and immunotherapy through timed monitoring and blood sample collection and to identify correlative biomarkers for predicting cardiopulmonary adverse events.

A Multi-Center Pilot Biomarker Study With Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy

Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy

Condition
Lung Cancer
Intervention / Treatment

-

Contacts and Locations

Columbia

University of Missouri - Ellis Fischel Cancer Center, Columbia, Missouri, United States, 65212

New Brunswick

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States, 08901

Rochester

University of Rochester Medical Center, Rochester, New York, United States, 14642

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patient older than 18 years age
  • * Diagnosis of locally advanced lung cancer (NSCLC or SCLC) with planned curative radiotherapy (45Gy and above) and planned consolidation immunotherapy.
  • * Patients who are not receiving concurrent chemotherapy and radiotherapy are eligible.
  • * Patients on a clinical trial that includes thoracic radiotherapy and immunotherapy are eligible and may be co-enrolled to this study.
  • * ECOG performance status of 0-2
  • * Life expectancy of 6 months or longer
  • * Patient able to provide a written informed consent prior to study entry
  • * Prior thoracic radiotherapy to chest.
  • * Patients are excluded if they are not candidates for curative thoracic radiotherapy or immunotherapy.
  • * Other severe acute or chronic medical or psychiatric condition that may increase the risk associated with study participation, and in the judgment of the investigator would make the subject inappropriate for entry into this study.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Bo Lu,

Bo Lu, MD, PRINCIPAL_INVESTIGATOR, Chair, Department of Radiation Oncology

Study Record Dates

2030-04-19